Rafal Farjo, Ph.D.

Chief Executive Officer

Dr. Farjo received his bachelor’s degree in Cell and Molecular Biology from the University of Michigan and his Ph.D. in Cell Biology from the University of Oklahoma. He has been involved in ocular research for over 10 years. During his time at the University of Michigan, Dr. Farjo worked to establish one of the first genomics core facilities at the university with a special emphasis on discovering genes and pathways associated with Age-Related Macular Degeneration. At the University of Oklahoma, Dr. Farjo’s research focused on the characterization of macular disease models and the development of new treatment options. During this tenure, he published the first study demonstrating the feasibility of using non-viral DNA nanoparticles as a method for gene therapy to ocular cells. He has also published in several prestigious journals, including The Journal of Cell Biology, Genome Biology, and Investigative Ophthalmology and Visual Sciences. At Charlesson, Dr. Farjo has raised over $5MM in non-dilutive federal and state funding for Charlesson’s research program.

Ophthalmic Contract Research